Therapeutic Science and Strategy

During the launch of a new medicine, there is so much focus on the intellectual strategy, that it's easy to sideline thoughts about "How are we going to collaborate as a team to make this happen?"

But statistics show that strong teamwork can deliver up to 3x more shareholder value. Investing time in good cross-functional collaboration is not just a nice-to-have, it's a must-have for successful launch teams.

In the first episode of our series on launch excellence, we explore the following:

• How strong internal collaboration delivers optimal launch outcomes
• Why a team 'contract' can transform a launch team's ways of workings
• The role leadership plays in driving cross-functional launch alignment and how much influence it delivers to success

Join Lumanity staff Tracey Barnes, Vice President of Launch Excellence, and Kirsty Tait, a leading Launch Excellence Consultant, as they untangle the intricacies of cross-functional collaboration to share what good launch teams are doing that sets them apart from the rest.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead at Lumanity, sits down to talk about relevant and important content. In this sixth episode, Joel sits down with the CEO and CMO of ImCheck Therapeutics to discuss:

• Company origins, focus, and fundraising performance to date
• Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity
• Performance of ICT01, Imcheck's clinical-stage lead program targeting BTN3A in gamma-delta T-cells
• Positioning and commercial strategy in the post-PD1 solid-tumor landscape

Episode Guests:

• Pierre d'Epenoux, CEO, ImCheck Therapeutics
• Paul Frohna, CMO, ImCheck Therapeutics

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fifth episode, Joel sits down with Brian Leyland-Jones, MB BS, PhD, CMO, National Foundation for Cancer Research and Peter Kuhn, PhD, Dean's Professor of Biological Sciences, Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology, to explore:

• Historical perspective on personalized approaches to cancer treatment
• Liquid biopsy as a means to facilitate adaptive treatment regimens tailored to individual cancers
• Vision of where the field is going and future management paradigms

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fourth episode, Joel sits down with Jeff Bockman, Executive Vice President and Head of Oncology at Lumanity, and Michael Curran, PhD, Associate Professor, Department of Immunology, The University of Texas, MD Anderson Cancer Center, to explore: • The effort to develop agents for the CPI resistant/refractory patients. Where do we biologically and clinically stand with this concept? • Whether IO remains a "spaghetti against the wall" approach, and what are we doing/can we do to drive more thoughtful programs forward, or more programs forward thoughtfully? • Thoughts about how Immuno-Oncology companies specifically should weather the current biotech winter

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this third episode, Joel sits down with Michael 'Mitch' Petrick, anaplastic thyroid cancer patient, to explore:

• Mitch's background and his rare form of thyroid cancer
• His journey from initial diagnosis (which he made!) through to referral and treatment
• Some thoughts about the drug development process and system from the perspective of someone in need of new solutions
• Lessons for drug manufacturers and healthcare providers

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this second episode, Joel sits down with Shivani Srivastava, PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center, to explore:

• Key challenges to addressing solid tumors with cell therapy
• Recent developments (technology, scientific understanding) that are lowering these barriers
• The ultimate promise offered by cell therapy for solid tumor patients (what a 'win' looks like)
• Thoughts about what can and will be achieved, and over what timeframe

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore:

• How uncovering NSCLC and SMA genetics led to record-speed options for patients with rare subtypes
• How the patient advocacy groups enabled translation
• How the provider infrastructure is evolving to meet the need for genetic precision
• What pharma brought upon entering and how the lessons shape their and field's outlook
• What's next for rare disease drug development

©2023 Lumanity Inc.